★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Stock Profile
Boston Scientific Corporation (BSX) Moat Analysis
Boston Scientific Corporation
BSX · New York Stock Exchange
Partial score covering 85% of segment weight.
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Boston Scientific is a global medical-device company focused on minimally invasive therapies across Endoscopy, Urology, Neuromodulation and Cardiovascular. Q1 2026 net sales were $5.203B, up 9.4% organically. The strongest supported moats are urology capital-system consumable pull-through, physician training and workflow familiarity in urology and neuromodulation, select regulatory clearances, and the CRM remote-monitoring installed base. Single-use products alone do not prove installed-base lock-in, GPO and tender participation does not prove procurement inertia, direct sales is not distribution control, and portfolio breadth does not establish scope economies; those claims are removed. Key risks are tender pressure, rapid peer innovation, safety events and reimbursement or regulatory shifts.
Primary segment
Cardiovascular
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
4 segments · 6 tags
Updated 2026-07-12
Segments
Endoscopy
Gastrointestinal and pulmonary endoscopy devices (incl. single-use endoscopy platforms and procedure disposables)
Revenue
14.5%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Urology
Urology devices (stone management, BPH, prostate cancer adjuncts, erectile dysfunction/incontinence implants) and related consumables
Revenue
13.5%
Structure
Competitive
Pricing
moderate
Share
—
Peers
Neuromodulation
Neuromodulation and pain-management devices (spinal cord stimulation, deep brain stimulation, nerve ablation and related systems)
Revenue
6%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Cardiovascular
Cardiovascular devices (interventional cardiology, vascular therapies, structural heart, electrophysiology, cardiac rhythm management, remote monitoring, and interventional oncology/embolization)
Revenue
66%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Endoscopy
Gastrointestinal and pulmonary endoscopy devices (incl. single-use endoscopy platforms and procedure disposables)
Revenue share computed from FY2025 net sales table: Endoscopy $2.916B of $20.074B total net sales.
Insufficient segment-specific evidence to assign a moat claim.
Urology
Urology devices (stone management, BPH, prostate cancer adjuncts, erectile dysfunction/incontinence implants) and related consumables
Revenue share computed from FY2025 net sales table: Urology $2.709B of $20.074B total net sales.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
A mix of capital systems and recurring, procedure-linked disposables (e.g., single-use scopes, laser fibers, accessories) supports repeat purchasing once a site standardizes.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Competitors offering similar single-use scopes and accessories
- Price compression on disposables as products commoditize
- Capital budget cycles shifting placements to rivals
Leading indicators
- Urology consumables growth vs procedure volumes
- Laser installed base growth and utilization
- Average selling price and gross margin trends
Counterarguments
- Hospitals can multi-source consumables, reducing switching costs
- If clinical differentiation narrows, purchasing shifts to price
Training Org Change Costs
Demand
Training Org Change Costs
Strength
Durability
Confidence
Evidence
Physician familiarity and workflow integration for device platforms (e.g., energy systems, implants, and procedural kits) creates friction to change vendors quickly.
Training Org Change Costs moat: definition, examples, and stocks
Erosion risks
- Competitors subsidizing training and switching programs
- New modalities or guidelines shifting standard-of-care
- Movement of procedures to lower-cost outpatient settings
Leading indicators
- Physician adoption rates for new platforms
- Share changes after major product launches
- Clinical guideline and reimbursement updates
Counterarguments
- Training costs are often one-time and can be offset by pricing concessions
- Standardization committees can force vendor switches despite physician preference
Neuromodulation
Neuromodulation and pain-management devices (spinal cord stimulation, deep brain stimulation, nerve ablation and related systems)
Revenue share computed from FY2025 net sales table: Neuromodulation $1.199B of $20.074B total net sales.
Regulated Standards Pipe
Legal
Regulated Standards Pipe
Strength
Durability
Confidence
Evidence
Regulatory approvals and the need for clinical evidence create barriers to entry and slow fast-follower competition in implantable/therapeutic neuromodulation.
Regulated Standards Pipe moat: definition, examples, and stocks
Erosion risks
- Regulatory changes increasing evidence requirements or delaying approvals
- Reimbursement reductions for pain/neuro procedures
- Safety signals or adverse events leading to restrictions/recalls
Leading indicators
- FDA/CE approvals and label expansions
- Coverage decisions and reimbursement rate updates
- Recall and adverse-event reporting trends
Counterarguments
- Large competitors can fund comparable trials and obtain their own clearances
- Regulatory barriers slow entrants but do not prevent differentiated substitutes
Training Org Change Costs
Demand
Training Org Change Costs
Strength
Durability
Confidence
Evidence
Complex implant and programming workflows (including proprietary programming software) make clinician training and familiarity important, raising switching friction.
Training Org Change Costs moat: definition, examples, and stocks
Erosion risks
- Standardized programming tools reducing learning differences across vendors
- Competitors accelerating adoption via aggressive training/incentives
- Shifts to non-implant alternatives for chronic pain
Leading indicators
- New implant starts and replacement volumes
- Training program throughput and clinician adoption
- Competitive win/loss in key accounts
Counterarguments
- Physicians can re-train; switching costs may be manageable over time
- Hospital value analysis committees can override clinician preference
Cardiovascular
Cardiovascular devices (interventional cardiology, vascular therapies, structural heart, electrophysiology, cardiac rhythm management, remote monitoring, and interventional oncology/embolization)
Revenue share computed from FY2025 net sales table: Cardiovascular $13.250B of $20.074B total net sales. Boston Scientific combined legacy Cardiology and Peripheral Interventions into Cardiovascular in Q4 2025 and revised prior periods to the current presentation.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Implantable CRM devices paired with remote monitoring/service obligations create recurring revenue and operational switching friction over the device/patient longevity period.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Interoperability mandates reducing monitoring platform stickiness
- Competitors bundling monitoring at lower cost
- Hospital standardization on alternative device ecosystems at replacement cycles
Leading indicators
- Deferred revenue balance tied to LATITUDE/LUX-Dx
- Installed base growth and patient monitoring adoption
- Replacement share in ICD/PM/ICM categories
Counterarguments
- Patients/device replacements create natural switch windows for competitors
- Remote monitoring is replicable and may become less differentiating over time
Evidence
LithoVue Single-Use Digital Flexible Ureteroscopes
Single-use ureteroscopes imply recurring revenue tied to procedure volume.
Holmium Laser Systems ... complemented by laser fibers and accessories
Shows an installed base of systems with ongoing consumables/accessory pull-through.
ease of use and physician familiarity
Physician familiarity is explicitly cited as a competitive factor, consistent with training and workflow switching costs.
Intracept ... the only FDA-cleared system to treat vertebrogenic pain
Example of a differentiated therapy position explicitly tied to FDA clearance.
subject to regulation ... including the FDA
Confirms regulatory oversight and approval pathways governing device commercialization.
Showing 5 of 9 sources.
Risks & Indicators
Erosion risks
- Competitors offering similar single-use scopes and accessories
- Price compression on disposables as products commoditize
- Capital budget cycles shifting placements to rivals
- Competitors subsidizing training and switching programs
- New modalities or guidelines shifting standard-of-care
- Movement of procedures to lower-cost outpatient settings
Leading indicators
- Urology consumables growth vs procedure volumes
- Laser installed base growth and utilization
- Average selling price and gross margin trends
- Physician adoption rates for new platforms
- Share changes after major product launches
- Clinical guideline and reimbursement updates
Research BSX elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.